LNTH News and Press, Lantheus Holdings Inc. From 10/22/19

On October 2nd, Lantheus Holdings ( LNTH ) Progenics Pharmaceuticals ( PGNX ), announced an agreement for Lantheus to acquire Progenics in an all-stock transaction. According to the press release, "the transaction has been unanimously approved by the Boards of Directors of both companies." U...

Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH) today announced that it will host a conference call at 8:00 a.m. ET on Thursday, October 31, 2019, to discuss its financial and operating results for the third quarter of 2019. To access the live conference call via te...

Merger activity increased last week with five new deals announced and five deals closing. Deal Statistics: New Deals: The acquisition of Dova Pharmaceuticals (DOVA) by Swedish Orphan Biovitrum AB (BIOVF) for $915 million. Under the terms of the agreement, Dova stockholders will ...

Lantheus Holdings' ( LNTH -20.9% ) all-stock deal to buy Progenics Pharmaceuticals ( PGNX +9.8% ) substantially undervalues the target company, says one of Progenics' biggest shareholders. More news on: Lantheus Holdings, Inc., Progenics Pharmaceuticals, Inc., Healthcare stocks news,...

Gainers : The Stars Group (NASDAQ: TSG ) +29% . Naked Brand Group (NASDAQ: NAKD ) +15% . Yuma Energy (NYSEMKT: YUMA ) +15% . Surface Oncology (NASDAQ: SURF ) +14% . Catalyst Biosciences (NASDAQ: CBIO ) +13% . NIO (NYSE: NIO ) +13% . Zynex (NASDAQ: ZYXI ) +11% . Aimmune Therapeutics ...

Shares of Lantheus Holdings (NASDAQ: LNTH) , a company focused on diagnostic medical imaging equipment and supplies , dropped 21% as of 10:35 a.m. EDT on Wednesday after the company announced that it is acquiring Progenics Pharmaceuticals (NASDAQ: PGNX) , a commercial-stage biotechnology ...

Lantheus Holdings (NASDAQ: LNTH ) agrees to acquire Progenics (NASDAQ: PGNX ) in an all-stock transaction, adding targeted medicines and artificial intelligence to find, fight, an follow cancer to its portfolio. More news on: Lantheus Holdings, Inc., Progenics Pharmaceuticals, Inc., Heal...

Highly Complementary Portfolio of Ultrasound and Radiopharmaceutical Diagnostics and Oncology Therapeutics Lantheus’ Proven Commercial, Manufacturing and Operational Excellence Well Positioned to Optimize the Combined Company’s Innovative Diagnostic and Radiopharmaceutic...

Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH), the parent company of Lantheus Medical Imaging, Inc. (“LMI”), a global leader in the development, manufacture and commercialization of innovative diagnostic imaging agents and products, today announced it ...

Merck (NYSE: MRK ) initiated with Outperform rating and $103 (23% upside) price target at SVB Leerink. Shares up  1%  premarket. More news on: Merck & Co., Inc., Livongo Health, Inc., Lantheus Holdings, Inc., Healthcare stocks news, Stocks on the move, , Read more ...